Effects of Angelicae tenuissima radix, Angelicae dahuricae radix and Scutellariae radix Extracts on Cytochrome P450 Activities in Healthy Volunteers

Basic and Clinical Pharmacology and Toxicology

Volumn 105, Issue 4, 2009, Pages 249-256

  Yi, Sojeong ^a   Cho, Joo Youn ^a   Lim, Kyoung Soo ^a   Kim, Kyu Pyo ^a   Kim, Jaewoo ^a   Kim, Bo Hyung ^a   Hong, Jang Hee ^b   Jang, In Jin ^a   Shin, Sang Goo ^a   Yu, Kyung Sang ^a  

^a Seoul National University   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGELICAE DAHURICAE RADIX EXTRACT; ANGELICAE TENUISSIMA RADIX EXTRACT; CAFFEINE; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DRUG METABOLITE; LOSARTAN; MIDAZOLAM; OMEPRAZOLE; PLANT EXTRACT; SCUTELLARIAE RADIX EXTRACT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME REGULATION; HERB DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADULT; ANGELICA; ARYL HYDROCARBON HYDROXYLASES; CAFFEINE; CHLORZOXAZONE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; DEXTROMETHORPHAN; DRUGS, CHINESE HERBAL; HERB-DRUG INTERACTIONS; HUMANS; LOSARTAN; MALE; MIDAZOLAM; OMEPRAZOLE; PHYTOTHERAPY; REPUBLIC OF KOREA; SCUTELLARIA BAICALENSIS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

SCUTELLARIA RADIX;

EID: 70349152524     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00423.x     Document Type: Article

References (42)

1. Ernst E. Herb-drug interactions: potentially important but woefully under-researched. Eur J Clin Pharmacol 2000 56 : 523 524.
2. Izzo AA. Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 2005 19 : 1 16.
3. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003 35 : 35 98.
4. Ueng YF, Shyu CC, Lin YL, Park SS, Liao JF, Chen CF. Effects of baicalein and wogonin on drug-metabolizing enzymes in C57BL/6J mice. Life Sci 2000 67 : 2189 2200.
5. Guo LQ, Taniguchi M, Chen QY, Baba K, Yamazoe Y. Inhibitory potential of herbal medicines on human cytochrome P450-mediated oxidation: properties of umbelliferous or citrus crude drugs and their relative prescriptions. Jpn J Pharmacol 2001 85 : 399 408.
6. Nakao M, Muramoto Y, Hisadome M, Yamano N, Shoji M, Fukushima Y et al. The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450 s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6. Eur J Clin Pharmacol 2007 63 : 345 353.
7. Ioannides C. Drug-phytochemical interactions. Inflammopharmacology 2003 11 : 7 42.
8. Tanaka E, Kurata N, Yasuhara H. How useful is the 'cocktail approach' for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J Clin Pharm Ther 2003 28 : 157 165.
9. Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br J Clin Pharmacol 2001 52 : 555 561.
10. Holland DT, Godfredsen KA, Page T, Connor JD. Simple high-performance liquid chromatography method for the simultaneous determination of serum caffeine and paraxanthine following rapid sample preparation. J Chromatogr B Biomed Sci Appl 1998 707 : 105 110.
11. Gonzalez HM, Romero EM, Chavez Tde J, Peregrina AA, Quezada V, Hoyo-Vadillo C. Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2002 780 : 459 465.
12. Frye RF, Stiff DD. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996 686 : 291 296.
13. Carrillo JA, Ramos SI, Agundez JA, Martinez C, Benitez J. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. Ther Drug Monit 1998 20 : 319 324.
14. Muchohi SN, Ward SA, Preston L, Newton CR, Edwards G, Kokwaro GO. Determination of midazolam and its major metabolite 1′-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. J Chromatogr B Analyt Technol Biomed Life Sci 2005 821 : 1 7.
15. Lam YW, Rodriguez SY. High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection. Ther Drug Monit 1993 15 : 300 304.
16. Furtek CI, Lo MW. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J Chromatogr 1992 573 : 295 301.
17. Iwasa T, Takano T, Hara K, Kamei T. Method for the simultaneous determination of losartan and its major metabolite, EXP-3174, in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 1999 734 : 325 330.
18. Zhu B, Ou-Yang DS, Cheng ZN, Huang SL, Zhou HH. Single plasma sampling to predict oral clearance of CYP3A probe midazolam. Acta Pharmacol Sin 2001 22 : 634 638.
19. Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 2001 11 : 781 791.
20. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996 6 : 121 149.
21. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 1996 6 : 159 176.
22. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995 57 : 662 669.
23. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995 5 : 358 363.
24. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002 71 : 89 98.
25. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 2003 43 : 84 91.
26. Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007 63 : 321 333.
27. Hu OY, Tang HS, Lane HY, Chang WH, Hu TM. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther 1998 285 : 955 960.
28. Ernstgard L, Warholm M, Johanson G. Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity. Br J Clin Pharmacol 2004 58 : 190 200.
29. Frye RF, Adedoyin A, Mauro K, Matzke GR, Branch RA. Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol 1998 38 : 82 9.
30. Ishihara K, Kushida H, Yuzurihara M, Wakui Y, Yanagisawa T, Kamei H et al. Interaction of drugs and Chinese herbs: pharmacokinetic changes of tolbutamide and diazepam caused by extract of Angelica dahurica. J Pharm Pharmacol 2000 52 : 1023 1029.
31. Kang JJ, Chen YC, Kuo WC, Chen T, Cheng YW, Kuo ML et al. Modulation of microsomal cytochrome P450 by Scutellariae radix and Gentianae scabrae radix in rat liver. Am J Chin Med 1996 24 : 19 29.
32. Kim BR, Kim DH, Park R, Kwon KB, Ryu DG, Kim YC et al. Effect of an extract of the root of Scutellaria baicalensis and its flavonoids on aflatoxin B1 oxidizing cytochrome P450 enzymes. Planta Med 2001 67 : 396 399.
33. Kim JY, Lee S, Kim DH, Kim BR, Park R, Lee BM. Effects of flavonoids isolated from Scutellariae radix on cytochrome P-450 activities in human liver microsomes. J Toxicol Environ Health A 2002 65 : 373 381.
34. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004 76 : 428 440.
35. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002 72 : 276 287.
36. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 2008 52 : 755 763.
37. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005 22 : 525 539.
38. Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK et al. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther 2008 83 : 61 9.
39. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005 77 : 415 426.
40. Tushar T, Vinod T, Rajan S, Shashindran C, Adithan C. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers. Basic Clin Pharmacol Toxicol 2007 100 : 269 272.
41. Yasar U, Dahl ML, Christensen M, Eliasson E. Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol 2002 54 : 183 185.
42. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A et al. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the 'Cooperstown cocktail'. Clin Pharmacol Ther 2000 68 : 375 383.